Opus Genetics (IRD) Return on Capital Employed (2018 - 2026)
Opus Genetics (IRD) reported Return on Capital Employed of 87.51% for Q1 2026, up 26453.0% year-over-year from N/an in Q1 2025, and up 19.74% quarter-over-quarter from 109.03% in Q4 2025.
Opus Genetics (IRD) Return on Capital Employed (2018 - 2026) Analysis & Trends
Opus Genetics (IRD) has 9 years of Return on Capital Employed data on file, last reported at 87.51% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 87.51%, up 26453.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 87.51% (up 26453.0% YoY), and the FY2025 annual result was 107.9%, up 7408.0% from the prior year.
- Return on Capital Employed rose to 87.51% in Q1 2026 per IRD's latest filing, from 109.03% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 64.73% in Q3 2023 and troughed at 784.63% in Q3 2025.
- A 5-year average of 129.66% and a median of 87.51% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 70393 bps in 2025, then jumped 26453 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 62.79% in 2022, then plunged by 134 bps to 21.11% in 2023, then tumbled by 976 bps to 227.12% in 2024, then soared by 52 bps to 109.03% in 2025, then climbed by 20 bps to 87.51% in 2026.
- Business Quant data shows IRD's Return on Capital Employed at 87.51% in Q1 2026, 109.03% in Q4 2025, and 784.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -87.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.51% |
| Dec 31, 2025 | -109.03% |
| Sep 30, 2025 | -784.63% |
| Jun 30, 2025 | -279.34% |
| Mar 31, 2025 | -352.04% |
| Dec 31, 2024 | -227.12% |
| Sep 30, 2024 | -80.70% |
| Jun 30, 2024 | -34.16% |
| Mar 31, 2024 | -25.77% |
| Dec 31, 2023 | -21.11% |
| Sep 30, 2023 | 64.73% |
| Jun 30, 2023 | 46.94% |
| Mar 31, 2023 | 43.22% |
| Dec 31, 2022 | 62.79% |
| Sep 30, 2022 | -163.44% |
| Jun 30, 2022 | -137.39% |
| Mar 31, 2022 | -119.73% |
| Dec 31, 2021 | -109.23% |
| Sep 30, 2021 | -141.63% |
| Jun 30, 2021 | -176.95% |